MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer
MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer
复制标题
MicroRNA 作为结直肠癌耐药性的调节剂、生物标志物和治疗靶点
DOI：
10.1159/000452525
复制
发表时间：
2016-01-01
影响因子：
--
通讯作者：
Chu, Xiaoyuan
中科院分区：
文献类型：
--
作者：
Xie, Tao;Huang, Mengxi;Chu, Xiaoyuan
化疗和靶向治疗是晚期结直肠癌的主要治疗手段.然而，对这些疗法的抗性是临床上的主要挑战。了解耐药的分子机制和开发有效的策略是非常需要的。越来越多的证据表明microRNAs（miRNAs）与结直肠癌耐药密切相关。这一领域知识的爆炸带来了新的预测和治疗机会。在这篇综述中，我们系统地总结了miRNA作为调节剂、组织或循环生物标志物以及治疗剂在CRC对5-氟尿嘧啶（5-FU）、奥沙利铂和抗EGFR治疗耐药中的作用。我们还讨论了潜在的悬而未决的问题和未来的方向有关这些进程。
Chemotherapy and targeted therapy are the main options for andvanced colorectal cancer (CRC). However, resistance to these therapies is a major challenge in the clinic. Understanding molecular mechanisms and developing effective strategies against the drug resistance are highly desired. Increasing evidence has revealed that microRNAs (miRNAs) are closely linked to drug resistance in CRC. The explosion of knowledge in this field has brought forward new predictive and therapeutic opportunities. In this review, we systemically summarize the roles of miRNAs as regulators, tissue or circulating biomarkers, and therapeutics in the CRC resistance to 5-fluorouracil (5-FU), oxaliplatin and anti-EGFR therapy. We also discuss the potential unsettled issues and future directions concerning these processes.